Nov 25, 2019 Oxbryta (voxelotor)approved by  the U.S. Food and Drug Administration  for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
More than 100,000 people in the U.S., and the more than 20 million globally sufferd with this blood disorder.Sickle cell disease is a lifelong, hereditary blood disorder in which red blood cells are peculiarly shaped (sickle  shape), which restricts the flow in blood vessels that limits oxygen delivery to the body’s tissues, leading to severe pain and organ damage.
Oxbryta inhibits red blood cell sickling, and improves red blood cell deformability (ability of a red blood cell to change shape)also  improves the ability of bloods flow. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-target-abnormality-sickle-cell-disease
